Insta
Zydus Cadila Seeks DCGI's Approval For Conducting Clinical Trials Of Antibody Cocktail To Treat Mild COVID-19
Zydus
Indian pharmaceutical major Zydus Cadila has sought approval from Drug Controller General of India (DCGI) for conducting trials of its monoclonal antibody cocktail to treat mild cases of Covid-19.
The development comes as the country is grappling with the second Covid wave.
According to Zydus, the treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials. The drugmaker added that the candidate was found to be safe and well-tolerated.
The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection, reports Hindustan Times.
"At this juncture, there is a critical need to explore safer and more efficacious treatments to combat COVID," Zydus Cadila's managing director, Sharvil Patel was quoted in the report as saying in an exchange filing.
Zydus Cadila is seeking national drugs controller’s permission to initiate phase 1/3 human clinical trials for its monoclonal antibodies.
It should be noted that similar treatments developed by US biotech and pharma firms including Vir Biotechnology and GSK, and Regeneron Pharmaceuticals have received emergency use nod from US Food and Drug Administration (FDA).
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
